Sangamo Therapeutics shares surge 45.54% after-hours after announcing $25M underwritten offering to raise capital.

Sangamo Therapeutics (SGMO) surged 45.54% in after-hours trading following the announcement of a $25.0 million underwritten offering, comprising 35.19 million shares and warrants, with pre-funded warrants and revised terms for existing investor warrants. The offering, priced at $0.4719 per share plus warrant, aims to raise capital for working capital and general corporate purposes. The move aligns with recent regulatory progress, including FDA Fast Track Designation for a pipeline candidate and positive trial data for its Fabry disease therapy, which had previously bolstered investor sentiment. The capital raise, combined with updated warrant terms to enhance liquidity, signaled to investors that Sangamo is addressing financial constraints while advancing key therapeutic programs, driving the sharp after-hours rally.